Taysha Gene Therapies, Inc. (TSHA) research
Taysha Gene Therapies, Inc.- Sector
- Biotechnology
- Last price
- $4.63
- As of
Taysha Gene Therapies, Inc. (TSHA): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-11.
As of . Source: SEC EDGAR filings for TSHA. Method and limitations.
Share the TSHA intelligence card
See the full TSHA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TSHA on one page. Preview it with sample data, then open it live with a free account.
Preview the TSHA dossierActive signals for TSHA
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1772% to TSHA (2026Q2)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 68% of TSHA (2026Q2)
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 9.3%, EPS $-0.13 vs $-0.1189 estimate
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 9.1% - EPS $-0.09 vs $-0.0825 estimate
- mediumEARNINGS_BEAT
Q4-2025: Beat consensus by 18.5% - EPS $-0.08 vs $-0.0981 estimate
FREE, NO ACCOUNT
Every signal on TSHA, as it fires
You are seeing 5 of 6 signals recorded on TSHA since 2026-05-17.
The five above landed across 3 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TSHA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 877619106 · 2026Q2 | $30M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 877619106 · 2026Q2 | $14.5M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 877619106 · 2026Q2 | $10.5M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 877619106 · 2026Q2 | $1.6M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TSHA
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
TSHA against its peers
TSHA's operating margin of -1130.6% ranks in the 21st percentile of 11 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | TSHA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 9.8M USD | 170M USD | 23 | 10 |
| Operating margin | -1130.6% | -85.3% | 21 | 11 |
| Net margin | -1115.3% | -85.4% | 21 | 11 |
| Return on equity | -44.1% | -50.2% | 55 | 18 |
Peers (20): ANAB, AVBP, MAZE, TYRA, INBX, SNDX, IMCR, RARE, RAPP, GHRS, ABSI, FBRX, DRTS, STOK, ORIC, NBTX, IMTX, NTLA, DMRA, VIR. Left out: KLRA (no annual filing), COAG (no annual filing), KALV (no annual filing), AAPG (period gap), KARD (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (TSHA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more TSHA signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to TSHAand get the insider, 13F, options, and confluence read in one view.